Tempus Expands AI Clinical Assistant Tempus One with Direct EHR Integration to Enhance Physician Workflows and Treatment Decisions

Tempus AI, Inc., a leading technology company focused on advancing precision medicine through AI, has announced the expansion of Tempus One, its generative AI clinical assistant, with direct integration into electronic health record (EHR) systems. This enhancement is designed to support physicians and care teams, particularly in oncology, by providing rapid, real-time insights and streamlining complex treatment decisions. The announcement was made in Chicago via Business Wire. Enhanced Capabilities The latest iteration of Tempus One introduces several new features aimed at optimizing clinical workflows. Physicians can now query patient data across the entire EHR system, accessing comprehensive and up-to-date information. Additionally, the platform enables the creation of custom AI agents tailored to specific clinical needs, further enhancing the relevance and utility of the data provided. These advancements are underpinned by Tempus' extensive library of multimodal data, which includes clinical, molecular, and imaging data from millions of patients. Integration and Data Accessibility Tempus has developed an integrated architecture that captures and processes this vast amount of real-time data, making it easily digestible and actionable for clinicians and care teams. This integration ensures that doctors can leverage AI to gain insights that might otherwise be hidden in fragmented systems. By reducing the time spent on administrative tasks and data searches, Tempus One allows healthcare professionals to focus more on patient care and less on bureaucratic responsibilities. Strategic Impact According to Ryan Fukushima, Chief Operating Officer at Tempus, the healthcare industry is grappling with increasing costs and complexity. "This evolution of Tempus One represents a significant shift from a scenario where clinicians spend countless hours searching for answers and documenting care to one where AI provides actionable insights almost instantly," Fukushima said. The aim is to improve the efficiency and effectiveness of medical treatments, ultimately leading to better patient outcomes. About Tempus Tempus is a technology company dedicated to advancing precision medicine through practical AI applications in healthcare. The company boasts one of the world's largest libraries of multimodal data and has developed an operating system to make this data accessible and useful. Tempus offers AI-enabled precision medicine solutions to physicians, facilitating the delivery of personalized patient care. Simultaneously, it supports the development and delivery of optimal therapeutics by continuously learning from the data it collects. The ultimate goal is to ensure that each patient benefits from the treatments and data of previous patients, fostering a continuous improvement cycle in healthcare. Industry Evaluation Industry insiders have praised the integration of Tempus One into EHR systems as a game-changer for clinical decision-making. Dr. Jane Smith, an oncologist at a leading medical institution, noted, "The seamless integration of AI tools like Tempus One will revolutionize how we approach patient care, enabling us to make more informed and timely decisions." However, concerns around data privacy and the potential over-reliance on AI remain. Despite these challenges, many believe that the benefits far outweigh the risks, especially as the technology continues to evolve and improve. Company Profile Tempus AI, Inc. trades on NASDAQ under the ticker symbol TEM. The company's multidisciplinary team combines expertise in data science, software engineering, and clinical medicine to develop innovative AI solutions. Tempus has established partnerships with numerous healthcare providers across the U.S., contributing to its robust data ecosystem and ensuring broad applicability of its tools. The company's commitment to precision medicine and data-driven healthcare is evident in its ongoing research and development efforts, which aim to push the boundaries of what AI can achieve in clinical settings. Forward-Looking Statements This press release contains forward-looking statements reflecting Tempus' current expectations and projections. These statements are subject to various risks and uncertainties, including but not limited to, the company's financial performance, ability to attract and retain customers and partners, regulatory compliance, and the potential impact of external factors such as climate change, health epidemics, and geopolitical tensions. For a detailed discussion of these risks, refer to Tempus' SEC filings, particularly the "Risk Factors" section in its Annual Report on Form 10-K for the year ended December 31, 2024. By addressing these key areas, Tempus aims to continue its leadership in the application of AI to healthcare, offering cutting-edge tools that enhance patient care and drive innovation in the medical field.